2023
National Trends in Racial and Ethnic Disparities in Use of Recommended Therapies in Adults with Atherosclerotic Cardiovascular Disease, 1999-2020
Lu Y, Liu Y, Dhingra L, Caraballo C, Mahajan S, Massey D, Spatz E, Sharma R, Rodriguez F, Watson K, Masoudi F, Krumholz H. National Trends in Racial and Ethnic Disparities in Use of Recommended Therapies in Adults with Atherosclerotic Cardiovascular Disease, 1999-2020. JAMA Network Open 2023, 6: e2345964. PMID: 38039001, PMCID: PMC10692850, DOI: 10.1001/jamanetworkopen.2023.45964.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseHistory of ASCVDCross-sectional studyLifestyle modificationPharmacological medicationsOptimal careCurrent careUS adultsEthnic differencesWhite individualsGuideline-recommended therapiesTotal cholesterol controlNon-Hispanic white individualsNutrition Examination SurveyLatino individualsQuality of careSelf-reported raceStatin useRecommended TherapiesSecondary preventionCholesterol controlOptimal regimensSmoking cessationEligible participantsExamination SurveyEligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey
Lu Y, Liu Y, Jastreboff A, Khera R, Ndumele C, Rodriguez F, Watson K, Krumholz H. Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey. Circulation Cardiovascular Quality And Outcomes 2023, 17: e010640. PMID: 37950677, PMCID: PMC10782930, DOI: 10.1161/circoutcomes.123.010640.Peer-Reviewed Original Research
2021
National Trends in Racial and Ethnic Disparities in Antihypertensive Medication Use and Blood Pressure Control Among Adults With Hypertension, 2011–2018
Lu Y, Liu Y, Dhingra LS, Massey D, Caraballo C, Mahajan S, Spatz ES, Onuma O, Herrin J, Krumholz HM. National Trends in Racial and Ethnic Disparities in Antihypertensive Medication Use and Blood Pressure Control Among Adults With Hypertension, 2011–2018. Hypertension 2021, 79: 207-217. PMID: 34775785, DOI: 10.1161/hypertensionaha.121.18381.Peer-Reviewed Original ResearchConceptsAntihypertensive medication usePoor hypertension controlOverall treatment rateLow control rateHypertension controlHypertension awarenessMedication useControl rateHispanic individualsEthnic differencesTreatment ratesBlack individualsGuideline-recommended medicationsBlood pressure controlWhite individualsNutrition Examination SurveyLow awareness rateAntihypertensive medicationsHypertensive peopleExamination SurveyIntensive medicationNational HealthAwareness rateEthnic disparitiesPressure controlContemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes
Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes. Journal Of The American Heart Association 2021, 10: e021084. PMID: 33998258, PMCID: PMC8403287, DOI: 10.1161/jaha.121.021084.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2Drug UtilizationEligibility DeterminationFemaleGlucagon-Like Peptide-1 ReceptorGuideline AdherenceHeart Disease Risk FactorsHumansIncretinsMaleMiddle AgedNutrition SurveysPractice Guidelines as TopicPractice Patterns, Physicians'Risk AssessmentSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeUnited StatesConceptsSGLT-2 inhibitorsType 2 diabetes mellitusAtherosclerotic cardiovascular diseaseChronic kidney diseaseLarge clinical trialsGLP-1RAsDiabetes mellitusCardiovascular diseaseHeart failureKidney diseaseClinical trialsHigh-risk atherosclerotic cardiovascular diseaseGLP-1RA useAmerican Diabetes AssociationNutrition Examination SurveyAnti-hyperglycemic agentsPublic health benefitsComplex survey designCardiovascular riskGuideline recommendationsDiabetes AssociationExamination SurveyProtective therapyNational HealthAmerican College
2018
Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study
Khera R, Lu Y, Lu J, Saxena A, Nasir K, Jiang L, Krumholz HM. Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study. The BMJ 2018, 362: k2357. PMID: 29997129, PMCID: PMC6039831, DOI: 10.1136/bmj.k2357.Peer-Reviewed Original ResearchConceptsACC/AHA guidelinesDiagnosis of hypertensionAge groupsHypertension guidelinesAHA guidelinesTreatment patternsCurrent guidelinesACC/AHA hypertension guidelinesHeart Association hypertension guidelinesCurrent treatment patternsIntensification of treatmentPrevalence of hypertensionNutrition Examination SurveyYears age groupUS National HealthYear old adultsSame age groupRetirement Longitudinal StudyAntihypertensive treatmentExamination SurveyNational HealthHypertensionAmerican CollegeChina HealthOlder adults
2011
Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure
Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure. The American Journal Of Medicine 2011, 124: 136-143. PMID: 21295193, PMCID: PMC3237399, DOI: 10.1016/j.amjmed.2010.08.017.Peer-Reviewed Original ResearchConceptsProportion of patientsHeart failureSelf-reported heart failureHeart failure populationComorbid chronic conditionsNumber of comorbiditiesNutrition Examination SurveyCare of patientsPrevalence of disabilityPhenotype of patientsComplexity of patientsMedication useRecent patientsFunctional disabilityExamination SurveyFailure populationPhysical functionPrescription medicationsPatient preferencesChronic conditionsNational HealthPatient's abilityComorbiditiesPatientsOlder individuals
2010
Beyond insurance coverage: Usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey
Spatz ES, Ross JS, Desai MM, Canavan ME, Krumholz HM. Beyond insurance coverage: Usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey. American Heart Journal 2010, 160: 115-121. PMID: 20598981, PMCID: PMC3025407, DOI: 10.1016/j.ahj.2010.04.013.Peer-Reviewed Original ResearchConceptsTreatment of hypertensionNutrition Examination SurveyInsurance statusMedication treatmentExamination SurveyNational HealthUsual sourceAdult Treatment Panel III recommendationsJoint National Committee 7Multivariable logistic regression modelingInsurance coverageSeparate multivariable modelsChronic disease managementLogistic regression modelingHigh-quality careRace/ethnicityCardiovascular diseaseMultivariable modelStratified analysisHypertensionHypercholesterolemiaRegular sourceCareDisease managementIndependent effects